338 related articles for article (PubMed ID: 19188163)
1. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.
Seavey MM; Pan ZK; Maciag PC; Wallecha A; Rivera S; Paterson Y; Shahabi V
Clin Cancer Res; 2009 Feb; 15(3):924-32. PubMed ID: 19188163
[TBL] [Abstract][Full Text] [Related]
2. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
Singh R; Paterson Y
Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
[TBL] [Abstract][Full Text] [Related]
3. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
Sinnathamby G; Lauer P; Zerfass J; Hanson B; Karabudak A; Krakover J; Secord AA; Clay TM; Morse MA; Dubensky TW; Brockstedt DG; Philip R; Giedlin M
J Immunother; 2009 Oct; 32(8):856-69. PubMed ID: 19752748
[TBL] [Abstract][Full Text] [Related]
4. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
Singh R; Dominiecki ME; Jaffee EM; Paterson Y
J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
[TBL] [Abstract][Full Text] [Related]
5. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
6. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
8. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
[TBL] [Abstract][Full Text] [Related]
9. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.
Gritzapis AD; Fridman A; Perez SA; La Monica N; Papamichail M; Aurisicchio L; Baxevanis CN
Vaccine; 2009 Dec; 28(1):162-70. PubMed ID: 19799847
[TBL] [Abstract][Full Text] [Related]
12. LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.
Rosenthal KS; Stone S; Koski G; Zimmerman DH
J Immunol Res; 2017; 2017():3613505. PubMed ID: 28459074
[TBL] [Abstract][Full Text] [Related]
13. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
14. Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma.
Chen Y; Yang D; Li S; Gao Y; Jiang R; Deng L; Frankel FR; Sun B
Oncogene; 2012 Apr; 31(17):2140-52. PubMed ID: 21927025
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
Gritzapis AD; Voutsas IF; Lekka E; Tsavaris N; Missitzis I; Sotiropoulou P; Perez S; Papamichail M; Baxevanis CN
J Immunol; 2008 Jul; 181(1):146-54. PubMed ID: 18566379
[TBL] [Abstract][Full Text] [Related]
16. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
18. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu as a target for cancer vaccines.
Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M
Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
